3SBio Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRSBF research report →
Companywww.3sbio.com
3SBio Inc. , an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy.
- CEO
- Jing Lou
- IPO
- 2018
- Employees
- 5,577
- HQ
- Shenyang, CN
Price Chart
Valuation
- Market Cap
- $6.38B
- P/E
- 4.83
- P/S
- 2.32
- P/B
- 1.51
- EV/EBITDA
- 2.86
- Div Yield
- 1.32%
Profitability
- Gross Margin
- 92.38%
- Op Margin
- 59.59%
- Net Margin
- 47.93%
- ROE
- 38.96%
- ROIC
- 26.48%
Growth & Income
- Revenue
- $17.24B · 89.27%
- Net Income
- $8.26B · 295.31%
- EPS
- $3.43 · 298.84%
- Op Income
- $10.29B
- FCF YoY
- 307.84%
Performance & Tape
- 52W High
- $4.74
- 52W Low
- $2.22
- 50D MA
- $2.80
- 200D MA
- $3.33
- Beta
- 0.56
- Avg Volume
- 817
Get TickerSpark's AI analysis on TRSBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TRSBF Coverage
We haven't published any research on TRSBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRSBF Report →